Wedbush reaffirmed their outperform rating on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research note issued to investors on Friday morning, 24/7 WallStreet reports. Wedbush currently has a $7.00 price target on the biotechnology company’s stock. Wedbush also issued estimates for Nabriva Therapeutics’ FY2023 earnings at $0.65 EPS.
Several other brokerages have also recently commented on NBRV. Bank of America set a $6.00 price objective on shares of Nabriva Therapeutics and gave the company a buy rating in a research note on Tuesday, August 20th. HC Wainwright set a $7.00 target price on shares of Nabriva Therapeutics and gave the company a buy rating in a report on Sunday, August 18th. Northland Securities set a $13.00 target price on shares of Nabriva Therapeutics and gave the company a buy rating in a report on Friday, August 16th. ValuEngine downgraded shares of Nabriva Therapeutics from a hold rating to a sell rating in a report on Thursday, November 14th. Finally, BidaskClub upgraded shares of Nabriva Therapeutics from a sell rating to a hold rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of Hold and an average target price of $6.79.
Shares of NBRV stock traded down $0.02 during mid-day trading on Friday, hitting $1.82. The stock had a trading volume of 9,064 shares, compared to its average volume of 753,581. Nabriva Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $3.27. The firm has a market cap of $1.39 billion, a PE ratio of -1.12 and a beta of 2.42. The company has a debt-to-equity ratio of 0.87, a current ratio of 5.81 and a quick ratio of 5.79. The company’s 50-day simple moving average is $1.92 and its 200-day simple moving average is $2.19.
Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. Nabriva Therapeutics had a negative net margin of 910.45% and a negative return on equity of 171.36%. The firm had revenue of $6.92 million during the quarter, compared to analysts’ expectations of $1.23 million. On average, analysts expect that Nabriva Therapeutics will post -1.12 EPS for the current year.
In other Nabriva Therapeutics news, CEO Theodore R. Schroeder bought 50,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was purchased at an average cost of $1.79 per share, for a total transaction of $89,500.00. Following the acquisition, the chief executive officer now owns 5,786 shares of the company’s stock, valued at approximately $10,356.94. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have acquired 64,977 shares of company stock valued at $119,951 and have sold 21,773 shares valued at $45,186. Company insiders own 3.32% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Sterling Investment Advisors Ltd. grew its holdings in shares of Nabriva Therapeutics by 100.0% during the third quarter. Sterling Investment Advisors Ltd. now owns 20,000 shares of the biotechnology company’s stock worth $40,000 after buying an additional 10,000 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV purchased a new stake in shares of Nabriva Therapeutics during the third quarter worth about $40,000. A.R.T. Advisors LLC purchased a new stake in shares of Nabriva Therapeutics during the second quarter worth about $90,000. Creative Planning purchased a new stake in shares of Nabriva Therapeutics during the third quarter worth about $112,000. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of Nabriva Therapeutics by 180.8% during the second quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock worth $127,000 after buying an additional 33,656 shares in the last quarter. Institutional investors and hedge funds own 3.82% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Article: What are convertible shares?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.